SYBX | tickerfilter.com

Fundamental analysis

18%

Profitability 0%

Dept financing 10%

Liquidity 66%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.06%

1 Month

0.01%

3 Months

-7.84%

6 Months

-7.84%

1 Year

-60.72%

2 Year

-87.21%

Key data

Stock price

$1.42

P/E Ratio

-0.31

DAY RANGE

$1.42 - $1.42

EPS

-$5.44

52 WEEK RANGE

$1.39 - $5.12

52 WEEK CHANGE

-$63.37

MARKET CAP

17.310 M

YIELD

N/A

SHARES OUTSTANDING

11.696 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.37

PUBLIC FLOAT

AVERAGE 10 VOLUME

$23,435

AVERAGE 30 VOLUME

$75,397

Company detail

CEO: Aoife M. Brennan
Region: US
Website: synlogictx.com
Employees: 80
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria and homocystinuria. The company is also developing SYNB1891 that is in Phase I clinical trial to treat solid tumors and lymphoma.

SYBX - SYNLOGIC, INC.